Nanosphere, Inc. (Nasdaq:NSPH),
a leader in the development and commercialization of advanced molecular diagnostics
systems, announced today that it has entered into an agreement with Eli Lilly
and Company (NYSE:LLY) to collaborate in connection with employing pharmacogenetic
assays in drug development initiatives. The two companies have signed the agreement
and the financial terms were not disclosed.
Nanosphere is developing the pharmacogenetic assays for use with its new Verigene
SP(r) system -- a sample-to-result, bench top molecular diagnostics instrument.
The turnkey and random access system uses whole blood and requires no PCR. It
allows for broad dissemination to recruitment sites which have no molecular
laboratories or to facilities already performing genetic testing.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics
platform, the Verigene(r) System, for direct genomic and ultra-sensitive protein
detection. This easy to use and cost effective platform enables simple, low
cost and highly sensitive genomic and protein testing on a single platform.
Nanosphere is based in Northbrook, IL. Additional information is available at